- ISIN
- US03836J1025
- CUSIP
- 03836J102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 3, 2019
Highlights
- Market Cap
- $4.03M
- Enterprise Value
- -$42.44M
- EPS (TTM)
- -$1.25
- Total Revenue (TTM)
- $118.11K
- Gross Profit (TTM)
- -$1.79M
- EBITDA (TTM)
- -$12.56M
- Year Range
- $0.55 - $1.83
- ROA (TTM)
- -25.11%
- ROE (TTM)
- -28.75%
- Avg. Volume (1M)
- 56K
- Avg. Volume Value (1M)
- $38.63K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
APRE Performance Chart
Aprea Therapeutics, Inc. (APRE) is down 27.3% since the beginning of the year. At $1 per share, APRE is trading 66.1% below its 52-week high of $2. Investors who bought $1,000 worth of APRE shares 5 years ago would now be looking at an investment worth $7.
Loading charts...
Compare this symbol against anything
Returns By Period
Aprea Therapeutics, Inc. (APRE) has returned -27.32% so far this year and -62.65% over the past 12 months.
Aprea Therapeutics, Inc.
- 1D
- -2.36%
- 1M
- -16.33%
- 6M
- -22.11%
- YTD
- -27.32%
- 1Y
- -62.65%
- 3Y*
- -41.52%
- 5Y*
- -62.59%
- 10Y*
- —
- ALL TIME*
- -59.75%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
APRE Monthly Returns History
Based on dividend-adjusted daily data since Oct 3, 2019, APRE's average daily return is -0.18%, while the average monthly return is -3.96%.
Historically, 35% of months were positive and 65% were negative. The best month was Dec 2019 with a return of +82.3%, while the worst month was Dec 2020 at -80.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, APRE closed higher 45% of trading days. The best single day was Jan 30, 2026 with a return of +34.9%, while the worst single day was Dec 28, 2020 at -78.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.68% | 15.16% | -16.78% | 4.85% | 11.59% | -10.12% | -22.72% | -27.32% | |||||
| 2025 | 18.84% | -35.20% | -19.48% | -14.71% | 0.00% | -2.87% | 0.59% | -7.94% | -5.75% | -5.08% | -10.00% | -32.30% | -74.07% |
| 2024 | 10.00% | 63.64% | -20.92% | -23.77% | -6.47% | -14.68% | -11.06% | -5.28% | -19.80% | 42.18% | -25.83% | 13.45% | -30.00% |
| 2023 | 51.51% | -48.85% | -13.45% | -10.70% | -2.90% | -18.18% | -1.59% | 19.35% | 12.61% | -19.36% | 8.33% | 29.12% | -29.00% |
| 2022 | -27.18% | -16.75% | 6.90% | -21.51% | -42.64% | -10.45% | 28.00% | -17.28% | -18.15% | 3.06% | -38.05% | -20.24% | -88.47% |
| 2021 | 12.20% | 9.24% | -15.42% | -8.04% | -10.02% | 15.64% | -13.32% | 9.22% | 10.61% | -3.13% | -18.38% | -28.96% | -41.67% |
Benchmark Metrics
Aprea Therapeutics, Inc. has an annualized alpha of -42.99%, beta of 0.70, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 03, 2019.
- This stock participated in 211.35% of S&P 500 Index downside but only -64.27% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -42.99%
- Beta
- 0.70
- R²
- 0.02
- Upside Capture
- -64.27%
- Downside Capture
- 211.35%
Return for Risk
Risk / Return Rank
APRE ranks 9 for risk / return — above 9% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Aprea Therapeutics, Inc. (APRE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| APRE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.15 | ||
| Sortino ratioReturn per unit of downside risk | -3.12 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 1.25 | -0.39 |
| Calmar ratioReturn relative to maximum drawdown | -0.95 | 2.00 | -2.95 |
| Martin ratioReturn relative to average drawdown | -1.38 | 8.49 | -9.87 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Aprea Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aprea Therapeutics, Inc. was 99.94%, occurring on Jan 29, 2026. The portfolio has not yet recovered.
The current Aprea Therapeutics, Inc. drawdown is 99.94%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.94%Jan 2026 | 6y 1mo | — | 6y 7moDec 2019 - now | — |
-24.77%Nov 2019 | 6d | 14d | 20dNov 2019 - Dec 2019 | — |
-17.45%Dec 2019 | 5d | 6d | 11dDec 2019 - Dec 2019 | — |
-8.92%Oct 2019 | 8d | 15d | 23dOct 2019 - Nov 2019 | — |
-7.61%Oct 2019 | 4d | 10d | 14dOct 2019 - Oct 2019 | — |
Drawdown Indicators
| APRE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.94% | -56.78% | -43.16% |
Max Drawdown (1Y)Largest decline over 1 year | -67.04% | -9.10% | -57.94% |
Max Drawdown (3Y)Largest decline over 3 years | -93.03% | -18.90% | -74.13% |
Max Drawdown (5Y)Largest decline over 5 years | -99.47% | -25.43% | -74.04% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.94% | -1.58% | -98.36% |
Average DrawdownAverage peak-to-trough decline | -85.68% | -10.70% | -74.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 46.11% | 2.14% | +43.97% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Aprea Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Aprea Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for APRE relative to other companies in the Biotechnology industry. Currently, APRE has a P/S ratio of 50.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for APRE in comparison with other companies in the Biotechnology industry. Currently, APRE has a P/B value of 0.2. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with APRE
Add Aprea Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with APRE